Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab after CCRT in locally advanced cervical cancer
NCT06391190Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Cervical Cancer (CC), sponsored by Renji Hospital. Started Jan 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06391190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391190.